Markus Renschler MD - 11 Dec 2023 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role: President and CEO, Director
Signature: /s/ David Gaiero, as attorney-in-fact for Markus Renschler, M.D.
Issuer symbol: N/A
Transactions as of: 11 Dec 2023
Net transactions value: +$13,697
Form type: 4
Filing time: 14 Dec 2023, 16:00:12 UTC
Previous filing: 22 Nov 2023
Next filing: 05 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	Common Stock	Options Exercise	$10,654	+6,304	+0.59%	$1.69	1,079,677	20 Nov 2023	Direct
transaction	CYT	Common Stock	Options Exercise	$3,043	+2,536	+0.23%	$1.20	1,082,213	20 Nov 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	Stock Option (Right to Buy)	Options Exercise	$0	-6,304	-2.6%	$0.000000	239,559	11 Dec 2023	Common Stock	6,304	$1.69	Direct	F1
transaction	CYT	Stock Option (Right to Buy)	Options Exercise	$0	-2,536	-50%	$0.000000	2,537	11 Dec 2023	Common Stock	2,536	$1.20	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F2	The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.